SCHEMBL21807965

SCHEMBL21807965

O=C(O)C1CCC(S(=O)(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.39
AKR1C3 P42330 1/20 0.38
AKR1C1 Q04828 1/20 0.38
TSHR P16473 4/20 0.38
LMNA P02545 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRA6 Q16445 2/20 0.38
CYP3A4 P08684 1/20 0.38
NFKB1 P19838 1/20 0.38
GABRR1 P24046 1/20 0.37
CYP2C19 P33261 2/20 0.35
PLG P00747 1/20 0.35
PLAT P00750 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7540083 0.86 TSHR (0.47) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL8384576 0.81 CYP2C19 (0.38) ACETSHRLMNAGABRA1GABRG2
SCHEMBL21987656 0.80 ACE (0.38) ACEAKR1C3AKR1C1TSHRLMNA
SCHEMBL21841486 0.80 LMNA (0.37) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL26478336 0.80 LMNA (0.37) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL26478444 0.80 LMNA (0.37) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL10953087 0.79 CYP2C19 (0.37) ACETSHRLMNAGABRA1GABRG2
SCHEMBL11096793 0.77 TSHR (0.50) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL30805682 0.77 LMNA (0.34) TSHRLMNAGABRA1GABRG2GABRB3
SCHEMBL18498492 0.75 TP53 (0.44) TSHRLMNAGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187668-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2025-01-07 US disclosed
EP-3334710-B1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-10-04 EP disclosed
EP-3334710-B1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-10-04 EP disclosed
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2023-05-04 US disclosed
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2023-05-04 US disclosed
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2023-05-04 US disclosed
CN-108026049-B Compositions and methods for treating and preventing neurodegenerative disorders 阿尔泽恩股份有限公司 2021-08-31 CN disclosed
US-11053192-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2021-07-06 US disclosed
US-11053192-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2021-07-06 US disclosed
US-20200347012-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2020-11-05 US disclosed
US-20200347012-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2020-11-05 US disclosed
US-10590070-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2020-03-17 US disclosed
US-10590070-B2 Compositions and methods for treating and preventing neurodegenerative disorders ALZHEON, INC. (US) 2020-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133465-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS PSEN2, CLN6, PSEN1 ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885
US-11053192-B2 Compositions and methods for treating and preventing neurodegenerative disorders PSEN2, CLN6, PSEN1 ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885
US-12187668-B2 Compositions and methods for treating and preventing neurodegenerative disorders PSEN2, CLN6, PSEN1 ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885
US-10590070-B2 Compositions and methods for treating and preventing neurodegenerative disorders PSEN2, CLN6, PSEN1 ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885
US-20200347012-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS PSEN2, CLN6, PSEN1 ACE 515/4885AKR1C3 2230/4885AKR1C1 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.